Intraperitoneal infusion of FAST CEA-targeted CAR-T

BIOLOGICAL2 trials

Sponsors

Weijia Fang, MD

Conditions

Colorectal CancerGastric CancerMetastatic CancerPancreatic CancerSolid CancersStomach Cancer

Phase 1

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

CompletedNCT05396300

Weijia Fang, MDColorectal Cancer, Gastric Cancer, Solid Cancers

Start: 2022-05-25End: 2026-06-30Updated: 2026-07-15

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

RecruitingNCT06821048

Weijia Fang, MDColorectal Cancer, Metastatic Cancer, Pancreatic Cancer +1

Start: 2024-07-24End: 2027-12-01Target: 18Updated: 2026-01-23

Related Papers

Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.

Journal of Clinical Oncology2026-05-27

Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.

2026-02-27

Removal: “Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer”

Therapeutic Advances in Medical Oncology2024-10-014 citations

Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.

Journal of Clinical Oncology2024-06-0116 citations